Antiviral treatment with sofosbuvir and simeprevir in a kidney transplant recipient with HCV-decompensated cirrhosis: Viral eradication and removal from the liver transplant waiting list

Transplant International

Volumn 28, Issue 11, 2015, Pages 1345-1349

  Bonacci, Martin ^a   Londoño, Maria Carlota ^a   Esforzado, Nuria ^b   Forns, Xavier ^a   Sotoca, Jose Miguel ^b   Campistol, Josep Maria ^b  

^a INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

cirrhosis; hepatitis C treatment; kidney transplant

Indexed keywords

RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TACROLIMUS; ANTIVIRUS AGENT; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CASE REPORT; CHILD PUGH SCORE; CHRONIC KIDNEY DISEASE; DECOMPENSATED LIVER CIRRHOSIS; DISEASE ASSOCIATION; DRUG SAFETY; FEMALE; FOCAL GLOMERULOSCLEROSIS; GRAFT RECIPIENT; HEPATITIS C; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LIVER BIOPSY; LIVER FIBROSIS; LIVER TRANSPLANTATION; MEDICAL PARAMETERS; MIDDLE AGED; PRIORITY JOURNAL; SUSTAINED VIROLOGICAL RESPONSE; TREATMENT INDICATION; VIRAL CLEARANCE; VIRUS LOAD; ALLOGRAFT; CHEMISTRY; COMPLICATION; GENOTYPE; GRAFT REJECTION; HEPACIVIRUS; HOSPITAL ADMISSION; KIDNEY; LIVER CIRRHOSIS; ORAL DRUG ADMINISTRATION; RENAL INSUFFICIENCY; TREATMENT OUTCOME; VIROLOGY;

ADMINISTRATION, ORAL; ALLOGRAFTS; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; GRAFT REJECTION; HEPACIVIRUS; HEPATITIS C; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; KIDNEY TRANSPLANTATION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MIDDLE AGED; RENAL INSUFFICIENCY; SIMEPREVIR; SOFOSBUVIR; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME; WAITING LISTS;

EID: 84932121758     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12622     Document Type: Article

References (20)

1. Vallet-Pichard A, Pol S,. Hepatitis C virus infection in hemodialysis patients. Clin Res Hepatol Gastroenterol 2013; 37: 340.
2. Fabrizi F, Aghemo A, Messa P,. Hepatitis C treatment in patients with kidney disease. Kidney Int 2013; 84: 874.
3. Goodkin DA, Bieber B, Gillespie B, Robinson BM, Jadoul M,. Hepatitis C infection is very rarely treated among hemodialysis patients. Am J Nephrol 2013; 38: 405.
4. Roth D, Gaynor JJ, Reddy KR, et al,. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol 2011; 22: 1152.
5. Fabrizi F, Penatti A, Messa P, Martin P,. Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol 2014; 86: 933.
6. Lens S, Gambato M, Londono MC, Forns X,. Interferon-free regimens in the liver-transplant setting. Semin Liver Dis 2014; 34: 58.
7. Lawitz E, Sulkowski MS, Ghalib R, et al,. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 2014; 384: 1756.
8. Londono MC, Abraldes JG, Altamirano J, Decaens T, Forns X,. Clinical trial watch: reports from the AASLD liver meeting(R), Boston, November 2014. J Hepatol 2015; 62: 1196.
9. Covic A, Abramowicz D, Bruchfeld A, et al,. Endorsement of the Kidney Disease Improving Global Outcomes (KDIGO) hepatitis C guidelines: a European Renal Best Practice (ERBP) position statement. Nephrol Dial Transplant 2009; 24: 719.
10. Afdhal N, Reddy KR, Nelson DR, et al,. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med 2014; 370: 1483.
11. Afdhal N, Zeuzem S, Kwo P, et al,. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370: 1889.
12. Zeuzem S, Dusheiko GM, Salupere R, et al,. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med 2014; 370: 1993.
13. Lawitz E, Matusow G, DeJesus E, et al,. A Phase 3, open-label, single-arm study to evaluate the efficacy and safety of 12 weeks of simeprevir (SMV) plus sofosbuvir (SOF) in treatment-naïve or -experienced patients with chronic HCV genotype 1 infection and cirrhosis: OPTIMIST-2. J Hepatol 2015; 62: S264.
14. Nelson DR, Cooper JN, Lalezari JP, et al,. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61: 1127.
15. Poordad F, Schiff E, Vierling J, et al,. Daclatasvir, sofosbuvir, and ribavirin combination for HCV patients with advanced cirrhosis or post-transplant recurrence: ALLY-1 phase 3 study. J Hepatol 2015; 62: S261.
16. Poordad F, Hezode C, Trinh R, et al,. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 2014; 370: 1973.
17. Reddy KR, Bourliere M, Sulkowski M, et al,. Ledipasvir and sofosbuvir in patients with genotype 1 HCV and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology 2015. doi: 10.1002/hep.27826.
18. Roth D, Nelson D, Bruchfeld A, et al,. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. J Hepatol 2015; 62: S263.
19. Pockros PJ, Reddy KR, Mantry PS, et al,. Safety of ombitasvir/paritaprevir/ritonavir plus dasabuvir for treating HCV G1 infection in patients with severe renal impairment of end-stage renal disease: the RUBY-I study. J Hepatol 2015; 62: S257.
20. Lin MV, Sise ME, Pavlakis M, et al,. Safety and efficacy of novel antivirals in kidney transplant recipients with chronic hepatitis C. J Hepatol 2015; 62: S284.